NCT07030621Not yet recruitingPhase 3
Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial
Source: ClinicalTrials.gov · Last updated 22 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The trial will be a randomized, double-blind, controlled, single-center trial. The purpose of this trial is to determine the efficacy and safety of semaglutide in improving neurological outcomes after endovascular thrombectomy for acute ischemic stroke. The patients in the treatment group will receive a subcutaneous injection of 0.5 mg semaglutide into the abdomen during endovascular thrombectomy. The patients in the control group will receive a similar-looking placebo. Patients will be randomized to the treatment or control group by the pharmacy, eliminating the selection bias. The patient and evaluator will be blind to the allocation of patients, further minimizing the bias.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 436 (estimated)
- First submitted
- 12 Jun 2025
- Start date
- 1 Jul 2025
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- RenJi Hospital
- Diseases
- Stroke
- NCT number
- NCT07030621
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 436
- From 1 Jul 2025 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Preoperative imaging diagnosis of intracranial hemorrhage, or history of intracranial hemorrhage within 3 months prior to surgery;
Other illness
- Recent history of ischemic stroke;
- Severe organic heart disease or severe arrhythmia;
- Contraindications to semaglutide or allergy to semaglutide.
Lab values
- Fasting blood glucose \<3.9 mmol/L;
Other
- Contraindications for endovascular thrombectomy;
- ASA classification of IV-V;
- Pregnant or lactating women;
Who the study is looking for
- Clinical or imaging diagnosis of acute ischemic stroke within 24 hours after onset;
- Scheduled for endovascular thrombectomy;
- Age ≥18 years;
- Pre-stroke modified Rankin Scale (mRS) score ≤1;
- Informed consent voluntarily signed by the patient or legal representative.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Renji Hospital Shanghai Jiao Tong University School of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.